23593-68-2Relevant articles and documents
FERROPORTIN INHIBITORS AND METHODS OF USE
-
Paragraph 0319; 0320, (2020/07/07)
The subject matter described herein is directed to Ferroportin inhibitor compounds of Formula I and pharmaceutical salts thereof, methods of preparing the compounds, pharmaceutical compositions comprising the compounds and methods of administering the compounds for prophylaxis and/or treatment of diseases caused by a lack of hepcidin or iron metabolism disorders, particularly iron overload states, such as thalassemia, sickle cell disease and hemochromatosis.
BENZOTRIAZEPINONE DERIVATIVES
-
Page/Page column 73-74, (2010/11/29)
The present invention is concerned with benzotriazepinone derivatives, their intermediates, uses thereof and processes for their production. In particular, the present invention relates to parathyroid hormone (PTH) and parathyroid hormone related protein (PTHrp) receptor ligands, (PTH-I or PTH/PTHrp receptor ligands). The invention also relates to methods of preparing such ligands and to compounds which are useful as intermediates in such methods.
Properties of a binaphthyl-bridged porphyrin - Iron complex bearing hydroxy groups inside its cavity
Kossanyi, Alain,Tani, Fumito,Nakamura, Nobu,Naruta, Yoshinori
, p. 2862 - 2872 (2007/10/03)
Hydrogen-bond formation with the terminal oxygen atom is considered to be the basis of dioxygen molecule activation by cytochrome P450. In order to verify the effect of this hydrogen bond, we have undertaken the synthesis of a model complex: a binaphthyl-